{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thymic+Carcinoma&page=3",
    "query": {
      "condition": "Thymic Carcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 51,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thymic+Carcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thymic+Carcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T20:42:08.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00020579",
      "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2001-03",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020579"
    },
    {
      "nct_id": "NCT03170804",
      "title": "Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Thyroid Nodule",
        "Thyroid Cancer",
        "Thyroid Diseases",
        "Thymic Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Aventura Hospital and Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2017-01-01",
      "completion_date": "2020-01-01",
      "has_results": false,
      "last_update_posted_date": "2017-05-31",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 1,
      "location_summary": "Aventura, Florida",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170804"
    },
    {
      "nct_id": "NCT01011439",
      "title": "Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thymic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Milciclib Maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tiziana Life Sciences LTD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2010-02-22",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2019-02-06",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Bethesda, Maryland",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011439"
    },
    {
      "nct_id": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Cutaneous Melanoma",
        "Carcinoma, Renal Cell",
        "Carcinoma, Ovarian Epithelial",
        "Nasopharyngeal Carcinoma",
        "Carcinoma, Thymic",
        "Anal Cancer",
        "Mesothelioma",
        "Esophagogastric Cancer",
        "High Microsatellite Instability Colorectal Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "KFA115",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 126,
      "start_date": "2022-10-26",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544929"
    },
    {
      "nct_id": "NCT00589290",
      "title": "Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thymoma",
        "Thymic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Belinostat (PDX101)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2007-12",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-09-30",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Bethesda, Maryland",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589290"
    },
    {
      "nct_id": "NCT00369889",
      "title": "A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thymic Cancer",
        "Thymoma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2006-08",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2014-06-03",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369889"
    },
    {
      "nct_id": "NCT03583086",
      "title": "Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thymic Carcinoma",
        "Non-small Cell Lung Cancer",
        "Refractory Thoracic Tumors",
        "Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Vorolanib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2018-07-10",
      "completion_date": "2024-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583086"
    },
    {
      "nct_id": "NCT06885697",
      "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mesothelioma",
        "Neoplasms",
        "Stomach Neoplasms",
        "Pancreatic Neoplasms",
        "Ovarian Neoplasms",
        "Lung Neoplasms",
        "Thymus Neoplasms",
        "Colonic Neoplasms"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "TNhYP218 CAR T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mesothelin expression testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 120,
      "start_date": "2025-07-08",
      "completion_date": "2044-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06885697"
    },
    {
      "nct_id": "NCT01100944",
      "title": "A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thymoma",
        "Thymic Carcinoma"
      ],
      "interventions": [
        {
          "name": "PXD101with cisplatin+doxorubicin+cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 26,
      "start_date": "2010-03-04",
      "completion_date": "2015-10-21",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100944"
    },
    {
      "nct_id": "NCT05461430",
      "title": "Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pleural Effusion, Malignant",
        "Ascites, Malignant",
        "Carcinoma",
        "Carcinoma, Hepatocellular",
        "Carcinoma, Renal Cell",
        "Carcinoma, Renal",
        "Carcinoma, Small Cell",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Pancreatic Ductal",
        "Carcinoma, Neuroendocrine",
        "Carcinoma, Thymic",
        "Carcinoma, Pancreatic",
        "Carcinoma Breast",
        "Carcinoma, Ovarian",
        "Carcinoma Bladder",
        "Carcinoma of Unknown Primary",
        "Carcinoma of the Head and Neck",
        "Carcinoma of the Oropharynx",
        "Carcinoma of the Larynx",
        "Carcinoma of the Bladder",
        "Carcinoma of Esophagus",
        "Carcinoma of the Nasopharynx",
        "Carcinoma of the Penis",
        "Carcinoma of the Cervix",
        "Carcinoma of the Anus",
        "Carcinoma of the Vulva",
        "Carcinoma of the Appendix",
        "Carcinoma of the Oral Cavity",
        "Cholangiocarcinoma",
        "Melanoma",
        "Mesothelioma",
        "Pancreatic Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Travera Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-07-15",
      "completion_date": "2026-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-04T20:42:08.408Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05461430"
    }
  ]
}